Sanjeev Luther, President and CEO to give an oral presentation and participate in a moderated panel discussion November 11, 2025…
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism…
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the…
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a…
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its…
November 03, 2025 16:45 ET | Source: Fulcrum Therapeutics, Inc. ― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell…
CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene…
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- EmblemHealth, one of the largest not-for-profit health insurers in the nation, today…
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…